Reliable quality of Semaglutide global trader 910463-68-2 Offer

Superiority:

Reliable quality of  Semaglutide global trader 910463-68-2 Offer

Clinical Phase II studies showed that somaglutide oral preparations were effective in reducing sugar and weight loss on February 20, 2015, and Novo Nord announced the results of the Phase II trial of somaglutide (OG217SC). After 26 weeks, HbA1c was reduced by 0.7% to 1.9% compared to the average 7.9% baseline of HbA1c, in a 26-week trial of 600 patients with type 2 diabetes, in five different doses of oral somaglutide 2.5-40 mg. Somaglutide injected with 1 mg under the skin was significantly better than in the placebo group, with HbA1c reduced more (1.9% vs. 0.3%). To determine the end of the trial, all oral doses of somaglutide were better than those in the placebo group.

In terms of weight loss, the subcutaneous injection somaglutide treatment group lost 5.6 kg of body weight compared to the average baseline weight of 92 kg, which is comparable to the maximum dose of oral somaglutide. The placebo, on the other part, had a maximum weight loss of only 1kg. Somaglutide has good safety and tolerance, common adverse reactions occur in the gastrointestinal tract, mainly nausea, vomiting, symptoms disappear over time. Gastrointestinal adverse reactions were dose-dependent, and the rate of adverse reactions at the maximum oral dose was higher than in the subcutaneous injection group. There was no significant difference in other adverse reactions between different treatment groups.